drugset / Trial / NCT04292769
Clinical Study of DC-CIK Cells as a Post-remission Treatment for Malignant Tumors
Non-randomizedParallel-groupOpen-labelPrevention
Summary
1. Screening stage 2. Evaluation of disease 3. Grouping of patients 4. Infusion of cells 5. Surveillance of adverse effect
Timeline
- Start
- 2020-01-21
- Primary completion
- 2023-01-20
- Completion
- 2023-01-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Decitabine | Small molecule | 10 mg | Intravenous |
| Background | DC-CIK | Cell therapy | — | — |